Answers are grounded in this paper and cite their sources.
Retrospective study evaluates treatment outcomes of PCd in patients with refractory multiple myeloma, suggesting efficacy.
Double‐ and triple‐refractory multiple myeloma (RRMM) still represents a considerable clinical challenge. Pomalidomide, cyclophosphamide and dexamethasone (PCd) remain a valid treatment option in this setting. This retrospective, multicentric study evaluated the activity and safety of PCd in patients with RRMM treated following standard clinical practice. A total of 179 patients were included. The median age was 72 years; most were triple‐refractory (59.8%), being 162 patients (90.5%) refractory to lenalidomide and 117 (65.4%) to anti‐CD38. The overall response rate (ORR) was 59.8% (95% CI: 52.2–67.0). Triple‐refractory patients had an ORR of 52.3% (95% CI: 42.5–62.1). The median progression‐free survival (PFS) and overall survival (OS) were 7.9 months (95% CI: 6.8–10.1) and 16.1 months (95% CI: 12.8–20.5), respectively. Patients refractory to lenalidomide and anti‐CD38 had a median PFS of 7.6 months (95% CI: 5.8–9.4) and 7.6 months (95% CI: 5.8–9.4), respectively. Most frequent grade 3–4 adverse events were neutropenia (57.5%), anaemia (30.7%) and thrombocytopenia (29.6%). PCd demonstrated effectiveness in double‐ and triple‐refractory RRMM patients, including those refractory to anti‐CD38 and is a viable treatment option for these patients.
No takes yet. Share an insight, caveat, or question.
Hidalgo-Soto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: